Loading [MathJax]/jax/output/SVG/jax.js
Review

MicroRNA-mediated regulation of BCL-2 in breast cancer

  • Received: 18 October 2024 Revised: 03 January 2025 Accepted: 13 January 2025 Published: 22 January 2025
  • Breast cancer, a prominent form of cancer in women, arises from the inner lining of mammary glands, ducts, and lobules. With an approximate prevalence rate of 1 in 8 women, the standard treatment methods for this condition include the surgical excision of afflicted tissues, chemotherapy, radiation, and hormone therapy. The BCL-2 gene, also known as the B cell lymphoma gene, prevents apoptosis in eukaryotic cells. It is commonly found to be excessively active in many types of malignancies, such as leukemia, carcinomas, and breast cancer. The excessive expression of this gene has a role in the advancement of cancer by inhibiting apoptosis. Recent research emphasizes the function of microRNAs (miRs) in regulating the expression of BCL-2. These miRs can either decrease or increase the activity of specific genes involved in programmed cell death, thus making them potential targets for therapeutic interventions. This review explicitly examines the regulatory impacts of several miRs on BCL-2, thereby investigating their ability to trigger apoptosis and function as targeted treatments for breast cancer. By comprehending the complex interplay between miRs and BCL-2, it is possible to devise novel therapeutic approaches that can augment the efficacy of breast cancer treatments, thus eventually enhancing patient outcomes.

    Citation: Kannan Mayuri, Sundaram Vickram, Thirunavukarasou Anand, Konda Mani Saravanan. MicroRNA-mediated regulation of BCL-2 in breast cancer[J]. AIMS Molecular Science, 2025, 12(1): 32-48. doi: 10.3934/molsci.2025003

    Related Papers:

    [1] Hui Xu, Jun Kong, Mengyao Liang, Hui Sun, Miao Qi . Video behavior recognition based on actional-structural graph convolution and temporal extension module. Electronic Research Archive, 2022, 30(11): 4157-4177. doi: 10.3934/era.2022210
    [2] Xite Yang, Ankang Zou, Jidi Cao, Yongzeng Lai, Jilin Zhang . Systemic risk prediction based on Savitzky-Golay smoothing and temporal convolutional networks. Electronic Research Archive, 2023, 31(5): 2667-2688. doi: 10.3934/era.2023135
    [3] Min Li, Ke Chen, Yunqing Bai, Jihong Pei . Skeleton action recognition via graph convolutional network with self-attention module. Electronic Research Archive, 2024, 32(4): 2848-2864. doi: 10.3934/era.2024129
    [4] Jiangtao Zhai, Haoxiang Sun, Chengcheng Xu, Wenqian Sun . ODTC: An online darknet traffic classification model based on multimodal self-attention chaotic mapping features. Electronic Research Archive, 2023, 31(8): 5056-5082. doi: 10.3934/era.2023259
    [5] Bingsheng Li, Na Li, Jianmin Ren, Xupeng Guo, Chao Liu, Hao Wang, Qingwu Li . Enhanced spectral attention and adaptive spatial learning guided network for hyperspectral and LiDAR classification. Electronic Research Archive, 2024, 32(7): 4218-4236. doi: 10.3934/era.2024190
    [6] Huimin Qu, Haiyan Xie, Qianying Wang . Multi-convolutional neural network brain image denoising study based on feature distillation learning and dense residual attention. Electronic Research Archive, 2025, 33(3): 1231-1266. doi: 10.3934/era.2025055
    [7] Chengyong Yang, Jie Wang, Shiwei Wei, Xiukang Yu . A feature fusion-based attention graph convolutional network for 3D classification and segmentation. Electronic Research Archive, 2023, 31(12): 7365-7384. doi: 10.3934/era.2023373
    [8] Zengyu Cai, Liusen Xu, Jianwei Zhang, Yuan Feng, Liang Zhu, Fangmei Liu . ViT-DualAtt: An efficient pornographic image classification method based on Vision Transformer with dual attention. Electronic Research Archive, 2024, 32(12): 6698-6716. doi: 10.3934/era.2024313
    [9] Shaohu Zhang, Jianxiao Ma, Boshuo Geng, Hanbin Wang . Traffic flow prediction with a multi-dimensional feature input: A new method based on attention mechanisms. Electronic Research Archive, 2024, 32(2): 979-1002. doi: 10.3934/era.2024048
    [10] Jiange Liu, Yu Chen, Xin Dai, Li Cao, Qingwu Li . MFCEN: A lightweight multi-scale feature cooperative enhancement network for single-image super-resolution. Electronic Research Archive, 2024, 32(10): 5783-5803. doi: 10.3934/era.2024267
  • Breast cancer, a prominent form of cancer in women, arises from the inner lining of mammary glands, ducts, and lobules. With an approximate prevalence rate of 1 in 8 women, the standard treatment methods for this condition include the surgical excision of afflicted tissues, chemotherapy, radiation, and hormone therapy. The BCL-2 gene, also known as the B cell lymphoma gene, prevents apoptosis in eukaryotic cells. It is commonly found to be excessively active in many types of malignancies, such as leukemia, carcinomas, and breast cancer. The excessive expression of this gene has a role in the advancement of cancer by inhibiting apoptosis. Recent research emphasizes the function of microRNAs (miRs) in regulating the expression of BCL-2. These miRs can either decrease or increase the activity of specific genes involved in programmed cell death, thus making them potential targets for therapeutic interventions. This review explicitly examines the regulatory impacts of several miRs on BCL-2, thereby investigating their ability to trigger apoptosis and function as targeted treatments for breast cancer. By comprehending the complex interplay between miRs and BCL-2, it is possible to devise novel therapeutic approaches that can augment the efficacy of breast cancer treatments, thus eventually enhancing patient outcomes.



    Tungiasis is a parasitic skin condition brought on by female sand fleas and is sometimes referred to as jiggers or sand flea infestation. Tropical and subtropical regions, especially the regions of America, Asia, Africa and the Caribbean, are infected with this disease. The flea enters into the skin, usually in areas where the skin is thin, such as the toes, heels and the spaces between toes and fingers [1]. The female sand flea burrows into the skin and grows into a small, swollen, and painful lesion, often resembling a tiny white or black dot. The flea then lays eggs inside this lesion and after development to complete the life cycle. The primary symptom of tungiasis is intense itching, leading to scratching, which can cause secondary bacterial infections. The affected area may become red, swollen, and painful. Over time, the lesions may grow larger and more uncomfortable [2]. Tungiasis is usually diagnosed based on clinical signs and symptoms. The presence of a specific lesion in the toes or feet, especially in areas with a history of sand flea infestations, helps with diagnosis [3]. The most effective treatment for tungiasis is the removal of the embedded sand fleas using sterilized instruments or a needle. The lesion should be cleaned and disinfected to prevent infections. In severe cases, topical antibiotics may be prescribed if secondary infections have developed [4]. Preventive measures include avoiding walking barefoot in sandy or contaminated areas and wearing protective footwear.

    Surgical extraction of embedded sand fleas under sterile medical conditions [5] can also be considered an efficacious therapeutic approach for its management. Tungiasis is a preventable condition, but it can cause significant discomfort and complications if left untreated [6]. If you suspect you have tungiasis or are experiencing symptoms, it is essential to seek medical attention for proper diagnosis and treatment. The infected areas often experience subpar living conditions and inadequate sanitation, making the inhabitants particularly susceptible to the infestation [7]. The afflicted populations face serious health and economical difficulties as a result of this neglected tropical illness. The mechanics of tungiasis transmission must be understood in order to adopt effective control measures and lessen the disease's effects. Jiggers, chigoe flea infection, and pulex penetrans infestation are a few of the historical names for tungiasis [8]. The female sand flea that transmits the disease burrows into the skin, concentrating on the feet, causing painful sores, inflammatory reactions, and secondary infections if left untreated.

    Mathematical models have significantly contributed to enhancing comprehension of the fundamental mechanisms of biological processes for public health [9][15]. Over the years, researchers and public health experts have dedicated significant efforts to gain insight into the spread of various infections [16]. Previous research has concentrated on a variety of disease-related topics [17], [18], from clinical symptoms and epidemiology to control methods and therapies. The frequency and geographic distribution of tungiasis have been examined in studies, revealing insight on the disease's burden and its effects on afflicted people [19], [20]. Kahuru et al conducted a study focused on employing an optimal control approach within a mathematical model to analyze the dynamics of tungiasis within a community [21]. The researchers in [22] established the stability results of the transmission dynamics of the disease. After that, the theory of optimal control is utilized, all with the ultimate goal of reducing the numbers of infested humans, infested animals, and sand flea populations [23]. The processes of disease transmission and the potential effects of interventions like better sanitation, health education, and treatment campaigns have both benefited greatly from these modeling studies [24]. Mathematical modeling of infectious diseases enhances our understanding of the diseases, facilitates evidence-based decision-making, and helps implement targeted interventions to reduce the burden of the condition in affected communities. In this work, we will enhance our scientific comprehension of tungiasis dynamics to provide more valuable perspectives for efficient management approaches. Through the utilization of mathematical modeling and simulation methods, we will evaluate the prospective consequences of treatments and facilitate decision-making within the realm of public health to improve the effectiveness of interventions and control measures.

    Fractional calculus is a branch of mathematics that deals with derivatives and integrals of non-integer orders. It extends the concepts of traditional calculus, which involves integer-order derivatives and integrals. Fractional calculus has found applications in various scientific fields [25][30], including epidemiology, where it can be used to model the spread of infectious diseases. It has been acknowledged that fractional calculus offers a more flexible framework for describing complex real-world problems [31], [32]. The Atangana-Baleanu fractional derivative is a type of fractional derivative that has been applied to various mathematical models, including epidemic models [33], [34]. Fractional calculus generalizes the concept of traditional derivatives and integrals to non-integer orders, allowing for a more flexible representation of complex phenomena, such as anomalous diffusion or power-law behaviors [35]. In the context of epidemic models, the Atangana-Baleanu fractional derivative has been utilized to introduce memory effects and long-range interactions into the system. In addition to this, these models can capture more realistic scenarios and provide insights into the long-term behavior of infectious diseases. Hence, we choose to represent the dynamics of tungiasis using a fractional framework to obtain more precise results.

    This article is organized as follows: The fundamental concepts and results of the fractional theory related to the ABC operator is presented in Section 2. In Section 3, we formulated a mathematical model for tungiasis through the ABC operator in the fractional framework. In Section 4, the suggested model is subsequently examined. In Section 5, the solution of the recommended model is investigated with the help of fixed-point theory. Then, we introduced a numerical scheme to highlight the dynamical behaviour of the system in Section 6. Finally, ending remarks of the work are presented with future work in Section 7.

    The main relevant findings and definitions of classical Caputo[36] and Atangana-Baleanu fractional derivatives[37] will be presented here and will be useful in the following portion of the paper.

    Definition 2.1. Let f:[p,q]R be a given function, then the fractional derivative of Caputo fractional derivative of order j is given by

    CpDjt(u(t))=1Γ(nj)tpun(κ)(tκ)nj1dκ,

    for j(n1,n), where nZ.

    Definition 2.2. The Atangana-Beleanu fractional derivative for a given function f in the Caputo form is introduced as

    ABCpDjtf(t)=B(j)1jtpf(κ)Ej[j(tκ)j1j]dκ,

    where fH1(p,q), q > p, and j[0,1]. In addition to this, B(j) is the normalization function which satisfies the condition B(0) = B(1) = 1.

    Definition 2.3. The integral of the ABC derivative is denoted by ABCpIjtf(t) and is defined as:

    ABCpIjtf(t)=1jB(j)f(t)+jB(j)Γ(j)tpf(κ)(tκ)j1dκ.

    Theorem 2.1. Assume f in a manner that fC[p,q], then we have the equation below mentioned in [37]:

    ABCpDȷt(f(t))<B(ȷ)1ȷf(t),wheref(t)=maxptq|f(t)|.

    Furthermore, it has been established that ABC derivatives satisfy the Lipschitz condition [37].

    ABCpDȷtf1(t)ABCpDȷtf2(t)<ϑ1f1(t)f2(t).

    Here we present a mathematical model of Tungiasis disease. In this approach, the total population is divided into four categories: group that practices good hygiene (P), susceptible (S), infected (I), and treated (T) groups. Then, the total population is

    N(t)=P(t)+S(t)+I(t)+T(t).

    At birth, the population that is most susceptible is recruited at a rate of (1γ)υ, whereas the group that practices good hygiene is recruited at γυ where υ represents the rate of recruitment at birth and γ represents the likelihood of being recruited into the category of good hygiene practices. The appropriate hygiene practice group (P) develops susceptibility (S) at a rate of φ. Individuals from the class (S) move to the class (I) with a rate Г. The infected individuals (I) transfer to the treated group (T) at a rate of ρ following therapy. We indicated the natural death rate by µ. The infection rate Г is defined as

    Γ=σεIN,

    where ϵ is the contact rate with infected people and σ is the likelihood of being infected after repeated exposure to infected people. Then our model with the above assumptions for tungiasis disease is as follows:

    {dPdt=γυ(φ+μ)P,dSdt=(1γ)υ+φP(Γ+μ)S,dIdt=ΓS(ω+ϱ+μ)I,dTdt=ϱIμT, (3.1)

    with appropriate initial condition

    P(0)>0, S(0)>0, I(0)>0, T(0)>0. (3.2)
    Table 1.  Parameter values with interpretation used in the proposed system.
    Parameter Interpretation
    γ Probability of recruitment in P(t)
    υ Birth or recruitment rate
    φ The losing rate of protection
    µ Death occurs naturally in each class
    Г Infection rate from susceptible to infected class
    ω Disease induced mortality rate
    ρ Treatment rate for the infection
    σ Rate of transmission of the infection
    ϵ Contact rate of infection

     | Show Table
    DownLoad: CSV

    It is acknowledged that epidemic models through the Atangana-Baleanu fractional derivative can more accurately represents the dynamics of infectious diseases than conventional integer derivatives. This inclusion enables a more comprehensive exploration of epidemic spread in intricate settings characterized by long-range interactions and memory effects, fostering an improved comprehension of the underlying mechanisms. Consequently, the refined insights gained from these fractional derivative-based models hold the potential to enhance the precision of epidemic predictions and facilitate the development of more efficacious control strategies. Nonetheless, it is crucial to acknowledge that the introduction of fractional derivatives into mathematical models may introduce increased system complexity, necessitating the utilization of specialized mathematical and numerical techniques for rigorous analysis and simulation. Thus, the model (3.1) recommended above can be written in fractional form as

    {ABC0DȷtP=γυ(φ+μ)P,ABC0DȷtS=(1γ)υ+φP(Γ+μ)S,ABC0DȷtI=ΓS(ω+ϱ+μ)I,ABC0DȷtT=ϱIμT. (3.3)

    All of the parameters in the recommended model (3.1) for tungiasis disease are considered to be positive. Furthermore, the term ABC0Djt in the above model indicates the ABC derivative. The effects of memory which arise in the epidemiological process but are not incorporated in the classical operators, are the driving force behind fractional order models. In Table 1, we illustrated the parameters of the recommended model with description.

    In this section, we deal with some analysis of the model, like steady-state analysis, and find the basic reproduction ratio R0 for the above model (3.3). As the system (3.3) models the population of humans, all state variable solutions with nonnegative beginning conditions are nonnegative t>0 and have a feasible region bound as follows:

    Ξ=((P,S,I,T)R4+;S,P,I,T0;Nυμ).

    In the upcoming step, we will focus on the steady-states of the suggested system of the infection. First, we take the following:

    ABC0DȷtP=ABC0DȷtS=ABC0DȷtI=ABC0DȷtT=0,

    then, the model (3.3) becomes

    {0=γυ(φ+μ)P,0=(1γ)υ+φP(Γ+μ)S,0=ΓS(ω+ϱ+μ)I,0=ϱIμT. (4.1)

    The disease-free equilibrium of an epidemic model refers to a stable state where the infectious disease has been eliminated from the population. Understanding the disease-free equilibrium is essential in assessing the effectiveness of control strategies and vaccination programs. It serves as a benchmark to measure the success of public health interventions in eliminating or controlling infectious diseases and preventing outbreaks. For the infection-free steady-state, we set

    P=Po,S=So,I=Io,T=To  and  N=No.

    Thus, we have

    Eo=(Po,So,Io,To)=(0,(1γ)υ(Γ+μ),0,0).

    The endemic equilibrium (EE) of an epidemic model refers to a stable state where the prevalence of the infectious disease remains constant over time. Understanding the endemic equilibrium of an epidemic model is crucial in assessing the long-term behavior of the infection and evaluating the quality of control measures in maintaining the disease at a manageable level. It provides valuable insights into the stability and persistence of the infection in a population and is a fundamental concept in the study of infectious disease dynamics. We indicate the EE of the system by (E*) and substitute Γ=σεIN. Then from (4.1), we have

    {0=γυ(φ+μ)P,0=(1γ)υ+φP(σεIN+μ)S,0=σεINS(ω+ϱ+μ)I,0=ϱIμT. (4.2)

    Solving the above system (4.2), we have

    E(PSIT)=E(γυφ+μN(ω+ϱ+μ)σε1(ω+ϱ+μ)[(φγμ+μ)υ(φ+μ)Nμ(ω+ϱ+μ)σε]ϱμ(ω+ϱ+μ)[(φγμ+μ)υ(φ+μ)Nμ(ω+ϱ+μ)σε]).

    The basic reproduction number is a fundamental concept in epidemiology that quantifies the potential of an infection to spread. It represents the average number of secondary infections generated by a single infected individual in a fully susceptible environment. If the basic reproduction number is less than 1, it means that, on average, each infected individual will cause fewer than one new infection during their infectious period. In this case, the disease will not be able to sustain itself in the population, and it will eventually die out. If this parameter is equal to 1, this implies that, on average, each infected individual will cause exactly one new infection during their infectious period. The disease will reach a stable endemic equilibrium, where the number of new infections is balanced by the number of recoveries, resulting in a constant prevalence of the disease in the population. If this parameter is greater than 1, this implies that each infected individual, on average, will cause more than one new infection during their infectious period. In this case, the disease has the potential to spread, and if left uncontrolled, it may lead to an epidemic outbreak.

    We symbolized this number as R0 and calculate it through the next-generation matrix method [38]. We take the infected class of the system (3.1), so we have

    ABC0DȷtI=ΓS(ω+ϱ+μ)I. (4.3)

    Let F be the matrix containing parameters that are entering into infected class and V be the matrix containing those parameters that leave infected classes while neglecting the negative signs, so we get

    F=ΓS=σεISN,

    and

    V=(ω+ϱ+μ)I.

    This implies that R0=σεω+ϱ+μ, which is the required R0 of the recommended system.

    Theorem 4.1. For j = 1, the infection-free steady-state E0 of the system (3.3) is locally asymptotically stable if R0<1, otherwise it is unstable.

    Proof. Let j = 1 and take the Jacobian matrix of the model (3.3) at infection-free steady-state E0 as

    J(Eo)=[(φ+μ)000φ(σεIoN+μ)σεIoN00σεIoNσεSoN(ϱ+ω+μ)000ϱμ].

    The above Jacobian matrix has the following characteristic equation:

    |J(Eo)λI|=0,

    furthermore, we have

    |(φ+μ)λ000φ(σεIoN+μ)λσεIoN00σεIoNσεSoN(ϱ+ω+μ)λ000ϱμλ|=0,

    and simplifying, we have

    ((φ+μ)λ)|(σεIoN+μ)λσεIoN0σεIoNσεSoN(ϱ+ω+μ)λ00ϱμλ|=0,

    which implies that λ1=(ϕ+µ) and

    |(σεIoN+μ)λσεIoN0σεIoNσεSoN(ϱ+ω+μ)λ00ϱμλ|=0,

    the simplification of which implies that

    (μλ)|(σεIoN+μ)λσεIoNσεIoNσεSoN(ϱ+ω+μ)λ|=0.

    From the above, we have λ2=µ and

    |(σεIoN+μ)λσεIoNσεIoNσεSoN(ϱ+ω+μ)λ|=0

    Hence, all the eigen values are negative. Furthermore, we have J1(E0) given by

    J1(E0)=[(σεIoN+μ)σεIoNσεIoNσεSoN(ϱ+ω+μ)]=0.

    To show the required result, we have to show that Tace(J1(Eo))<0 and Det(J1(Eo))>0, so

    Trace(J1(Eo))=(σεIoN+μ)+σεSoN(ϱ+ω+μ),
    =μ+σε(ϱ+ω+μ),
    =μ+σεϱωμ,
    =2μ+σε(ϱ+ω),
    Trace(J1(E0))=(2μσε+(ϱ+ω))<0,

    which implies that

    Trace(J1(Eo))<0.

    Also, we have

    Det(J1(E0))=|(σεIoN+μ)σεIoNσεIoNσεSoN(ϱ+ω+μ)|
    =[(σεIoN+μ)(σεSoN(ϱ+ω+μ))(σεIoN)(σεIoN)].

    Because R0<1 is given, so the Det will be positive, that is, Det(J1(E0))>0. Hence, the infection-free steady-state of the recommended system is locally asymptotically stable (LAS) for R0<1 and unstable in other cases.

    Theorem 4.2. For j = 1, the endemic steady-state (E*) of system (3.3) is LAS if R0>1 and is unstable in other circumstances.

    Proof. Let j = 1 and take the Jacobian matrix of system (3.3) at endemic steady-state (E*) as

    J(E)=[(φ+μ)000φ(σεIN+μ)σεIN00σεINσεSN(ϱ+ω+μ)000ϱμ,],

    furthermore, we get

    J(E)=[(φ+μ)000φ(σεWN+μ)σεWN00σεWN(ϱ+ω+μ)000ϱμ,],

    in which W=1(ω+ϱ+μ)[(φγμ+μ)υ(φ+μ)Nμ(ω+ϱ+μ)σε]. The characteristic equation is (φ+μ+λ)(μ+λ)[λ2+(σεWN+μ)λ+σε(ω+ϱ+μ)WN]=0, which implies that λ1=(ϕ+µ) and λ2=µ with the following

    λ2+(σεWN+μ)λ+σε(ω+ϱ+μ)WN=0. (4.4)

    Substituting the value of W into (4.4), we get

    λ2+mλ+n=0, (4.5)

    in which m=Ro((φγμ+μ)υ)(φ+μ)N and n=σε(φγμ+μ)υ(φ+μ)N(ω+ϱ+μ)μ. Hence it is clear that m,n>1, also R0=σεω+ϱ+μ>1. The eigenvalues provided by equation (4.5) are negative according to the Routh-Hurwitz criteria. Thus, whenever R0>1, the EE of the proposed model of tungiasis is locally asymptotically stable.

    In this section of the paper, we utilize fixed point theory to demonstrate the existence and uniqueness of the fractional order model (3.3) solution. The system of equations can be represented in the following way:

    {ABC0Dȷts(t)=U(t,v(t)),v(0)=v0,0<t<T<. (5.1)

    In the above (5.1), v(t)=(P,S,I,T) is the vector form of the state variables and U is a continuous vector function. Moreover, U is given by

    U=(U1U2U3U4)=(γυ(φ+μ)P,(1γ)υ+φP(Γ+μ)S,ΓS(ω+ϱ+μ)I,ϱIμT),

    and v0(t)=(P(0),S(0),I(0),T(0)) are initial conditions. In addition to this, the Lipschitz condition is fulfilled by U as

    U(t,v1(t))U(t,v2(t))Nv1(t)v2(t). (5.2)

    In the upcoming step, the existence and uniqueness of the fractional order dynamical model (3.3) will be proved.

    Theorem 5.1. The solution of fractional order (FO) model of equations (3.3) will be unique if the below mentioned condition satisfies:

    (1ȷ)ABC(ȷ)N+ȷABC(ȷ)Γ(ȷ)TȷmaxN<1. (5.3)

    Proof. In order to demonstrate the desired result, we utilize the Atangana-Beleanu (AB) fractional integral, as defined in (2.3), on system (5.1). This yields a non-linear Volterra integral equation as follows:

    v(t)=v0+1ȷABC(ȷ)U(t,r(t))+ȷABC(ȷ)Γ(ȷ)t0(tκ)ȷ1U(κ,v(κ))dκ. (5.4)

    Take I=(0,T) and the operator Φ:G(I,R4)G(I,R4) defined by

    Φ[v(t)]=v0+1ȷABC(ȷ)U(t,v(t))+ȷABC(ȷ)Γ(ȷ)t0(tκ)ȷ1U(κ,v(κ))dκ. (5.5)

    Equation (5.4) takes the following form

    v(t)=Φ[v(t)], (5.6)

    and the supremum norm on I is indicated by .I and is

    v(t)I=suptIv(t),v(t)G. (5.7)

    Certainly, G(I,R4) with norm .I becomes a Banach space and

    t0F(t,κ)v(κ)dκTF(t,κ)Iv(t)I, (5.8)

    with v(t)G(I,R4), F(t,κ)G(I2,R) in a manner that

    F(t,κ)I=supt,κI|F(t,κ)|. (5.9)

    Here, utilizing the definition of Φ shown in (5.6), we have

    Φ[v1(t)]Φ[v2(t)]I(1ȷ)ABC(ȷ)(U(t,v1(t))U(t,v2(t))+ȷABC(ȷ)Γ(ȷ)×t0(tκ)ȷ1(U(κ,v1(κ))U(κ,v2(κ)))dκI (5.10)

    Additionally, by applying the Lipschitz condition (5.2) and the triangular inequality, in combination with the result in (5.8), we arrive at the below expression after simplification:

    Φ[v1(t)]Φ[v1(t)]I((1ȷ)NABC(ȷ)+ȷABC(ȷ)Γ(ȷ)NTȷmax)v1(t)v2(t)I. (5.11)

    Consequently, we have the following:

    Φ[v1(t)]Φ[v1(t)]IBv1(t)v2(t)I, (5.12)

    in which

    B=(1ȷ)NABC(ȷ)+ȷABC(ȷ)Γ(ȷ)NTȷmax.

    It is evident that when condition (5.3) is met, Φ becomes a contraction, implying that the fractional order dynamical system (5.1) possesses a unique solution.

    In this section, we will present an iterative scheme for the numerical solution of the recommended model (3.3) of the infection. First, an iterative scheme will be developed and then the the solution pathways of the system will be represented through the scheme to understand the dynamics. We use the newly established numerical approach (iterative) proposed for the approximation of the AB integral operator [39]. We briefly describe and apply the aforesaid approach to our dynamical system (3.3) in order to show the impact of different parameters on the infection.

    Here, rewriting system (5.4) of the infection into the fractional integral equation form using the fundamental theorem of fractional calculus:

    s(t)s(0)=(1ȷ)ABC(ȷ)U(t,s(t))+ȷABC(ȷ)×Γ(ȷ)t0U(κ,x(ξ))(tκ)ȷ1dξ. (6.1)

    At t=tξ+1, ξ=0,1,2,..., we have

    s(tξ+1)s(0)=1ȷABC(ȷ)U(tξ,s(tξ))+ȷABC(ȷ)×Γ(ȷ)tξ+10U(κ,s(κ))(tξ+1κ)ȷ1dȷ,=1ȷABC(ȷ)U(tξ,s(tξ))+ȷABC(ȷ)×Γ(ȷ)ξj=0tj+1tjU(κ,s(κ))(tξ+1κ)ȷ1dȷ. (6.2)

    The function U(κ,s(κ)) can be estimated over the interval [tj,tj+1], and we apply the interpolation polynomial

    U(κ,s(κ))U(tj,s(tj))h(ttj1)U(tj1,s(tj1))h(ttj), (6.3)

    then substituting in (6.2), we get

    s(tξ+1)=s(0)+1ȷABC(ȷ)U(tξ,s(tξ))+ȷABC(ȷ)×Γ(ȷ)ξj=0(U(tj,s(tj))htj+1tj(ttj1)(tξ+1t)ȷ1dtU(tj1,s(tj1))htj+1tj(ttj)(tξ+1t)ȷ1dt). (6.4)

    After computing these integrals, the approximate answer is as follows:

    s(tξ+1)=s(t0)+1ȷABC(ȷ)U(tξ,s(tξ))+ȷABC(ȷ)ξj=0(hȷU(tj,s(tj))Γ(ȷ+2)((ξ+1j)ȷ(ξj+2+ȷ)(ξj)ȷ(ξj+2+2ȷ))hȷU(tj1,s(tj1))Γ(ȷ+2)((ξ+1j)ȷ+1(ξj)ȷ(ξj+1+ȷ))). (6.5)

    Finally, for the suggested model, we achieved the following recursive formulae:

    P(tξ+1)=P(t0)+1ȷABC(ȷ)U1(tξ,s(tξ))+ȷABC(ȷ)ξj=0(hȷU1(tj,s(tj))Γ(ȷ+2)((ξ+1j)ȷ(ξj+2+ȷ)(ξj)ȷ(ξj+2+2ȷ))hȷU1(tj1,s(tj1))Γ(ȷ+2)((ξ+1j)ȷ+1(ξj)ȷ(ξj+1+ȷ)))S(tξ+1)=S(t0)+1ȷABC(ȷ)U2(tξ,s(tξ))+ȷABC(ȷ)kj=0(fȷU2(tj,s(tj))Γ(ȷ+2)((ξ+1j)ȷ(ξj+2+ȷ)(ξj)ȷ(ξj+2+2ȷ))hȷU2(tj1,s(tj1))Γ(ȷ+2)((ξ+1j)ȷ+1(ξj)ȷ(ξj+1+ȷ)))I(tξ+1)=I(t0)+1ȷABC(ȷ)U3(tξ,s(tξ))+ȷABC(ȷ)ξj=0(hȷU3(tj,s(tj))Γ(ȷ+2)((ξ+1j)ȷ(ξj+2+ȷ)(ξj)ȷ(ξj+2+2ȷ))hȷU3(tj1,s(tj1))Γ(ȷ+2)((ξ+1j)ȷ+1(ξj)ȷ(ξj+1+ȷ)))T(tξ+1)=T(t0)+1ȷABC(ȷ)U4(tξ,s(tξ))+ȷABC(ȷ)ξj=0(fȷU4(tj,s(tj))Γ(ȷ+2)((ξ+1j)ȷ(ξj+2+ȷ)(ξj)ȷ(ξj+2+2ȷ))fȷU4(tj1,s(tj1))Γ(ȷ+2)((n+1j)ȷ+1(ξj)ȷ(ξj+1+ȷ))). (6.6)
    Figure 1.  Visualization of the tracking path behavior of the suggested model under varying fractional parameter values j, i.e., j = 0.5, 0.6, 0.7, 0.8.
    Figure 2.  Illustration of the solution pathways of the suggested model with varying values of the losing rate of protection φ, i.e., φ = 0.40, 0.45, 0.50, 0.55.
    Figure 3.  Illustration of the solution pathways of the suggested model with varying values of the treatment rate ρ, i.e., ρ = 0.02, 0.04, 0.06, 0.08.
    Figure 4.  Representing the time series of the class of the proposed system of the infection with varying values of the transmission probability σ, i.e., σ = 0.40, 0.50, 0.60, 0.70.
    Figure 5.  Visualization of the tracking path behavior of the suggested model under varying fractional parameter values j, i.e., j = 0.85, 0.90, 0.95, 1.00.

    We will utilize the above alterative approach to investigate the dynamical behaviour of the recommended fractional model of tungiasis. It is well-known that the graphical view analysis of epidemic models provide a comprehensive exploration of the model's behavior, leading to a better understanding of the epidemic's spread and potential control strategies. Here, we will perform different simulations to visualize the impact of different input factors on the system.

    The values of the input parameter and state variables of the system are assumed for numerical purposes. For our investigation, we conducted a series of simulations to analyze the behavior of the system under different conditions. In these simulations, we varied specific parameters and observed their impact on the solution pathways of the system. First, in Figure 1 and Figure 5, we examined the effect of the fractional parameter j on the dynamics of the system. By changing the fractional order, we aimed to understand its role in shaping the infection spread in the society. Notably, we observed that decreasing the fractional parameter led to a reduction in the infection rate within the community. This finding indicates that the fractional parameter can serve as a crucial control parameter for managing the epidemic. In Figure 2, we focused on the losing rate of protection and its influence on the dynamics of the tungiasis infection. The results clearly indicate that this parameter plays a pivotal role in determining the risk of infection within the population. A higher losing rate of protection was found to increase the susceptibility to infection, posing a potential threat to public health.

    The treatment rate was the primary parameter of interest in Figure 3. By varying the treatment rate ρ, we explored its impact on the transmission dynamics of the system. The simulation revealed that the treatment rate significantly affects the control of the infection. Higher values of ρ demonstrated a more effective reduction in infection rates, suggesting its importance in implementing effective intervention strategies. Lastly, Figure 4 focused on understanding the influence of the transmission probability on the tungiasis dynamics. Through this simulation, we visualized how changes in the transmission probability affect the overall dynamics of the infection. The results clearly illustrated that the transmission probability is a critical factor in shaping the infection spread within the community.

    Our numerical analysis provided valuable insights into the control and dynamics of tungiasis. The fractional parameter, losing rate of protection, treatment rate, and transmission probability all emerged as significant factors that influence the infection's behavior. In the realm of tungiasis control and intervention, our discovered insights provide a foundational framework for the formulation of effective strategies aimed at managing and mitigating the spread of the infection within affected populations. It is, however, crucial to acknowledge that the values employed in this analysis were assumptions crafted for numerical expediency and may not faithfully replicate real-world scenarios. Consequently, for heightened precision in predictions and practical implications, an imperative next step involves the meticulous validation and refinement of our model using authentic real-world data. This process is indispensable for aligning our theoretical framework with the intricacies of tangible scenarios and enhancing the applicability of our findings in the context of tungiasis control and management.

    In this study, we formulated an epidemic model for tungiasis disease in the framework of fractional Atangana-Baleanu derivative to conceptualize the transmission route of the infection. The biologically meaningful steady-states of the system are investigated through analytic methods. We determined the basic reproduction number of our fractional model, symbolized by R0. The existence and uniqueness of the model's solution has been demonstrated. We have shown that the infection-free steady-states of the recommended model are locally asymptotically stable if R0<1 and unstable in other cases, while the endemic steady-state is locally asymptotically stable if R0>1 and unstable in other circumstances. A numerical scheme is presented to illustrate the solution pathways of the recommended system of the infection. The dynamical behaviour of the model is presented with the variation of different input parameters. We recommended the most critical factors of the system for the control and subsequent of tungiasis. It is acknowledged that delays play a fundamental role in capturing the temporal dynamics of systems [40]. Incorporating delays into mathematical models enhances their predictive power and allows for a more accurate representation of real-world phenomena [41][43]. In the future work, we will incorporate time delay in the transmission dynamics of the disease to comprehend the dynamics of the disease and provide more accurate information for prevention.

    The authors declare they have not used Artificial Intelligence (AI) tools in the creation of this article.


    Acknowledgments



    The institutional ethics committee of the Bharath Institute of Higher Education and Research approved all the research protocols.

    Conflict of interest



    The authors declare no conflicts of interest.

    [1] Wilkinson L, Gathani T (2022) Understanding breast cancer as a global health concern. Br J Radiol 95: 20211033. https://doi.org/10.1259/bjr.20211033
    [2] Bland KA, Mustafa R, McTaggart-Cowan H (2023) Patient preferences in metastatic breast cancer care: A scoping review. Cancers 15: 4331. https://doi.org/10.3390/cancers15174331
    [3] Bhushan A, Gonsalves A, Menon JU (2021) Current state of breast cancer diagnosis, treatment, and theranostics. Pharmaceutics 13: 723. https://doi.org/10.3390/pharmaceutics13050723
    [4] Pankotai-Bodó G, Oláh-Németh O, Sükösd F, et al. (2024) Routine molecular applications and recent advances in breast cancer diagnostics. J Biotechnol 380: 20-28. https://doi.org/10.1016/j.jbiotec.2023.12.005
    [5] Amethiya Y, Pipariya P, Patel S, et al. (2022) Comparative analysis of breast cancer detection using machine learning and biosensors. Intell Med 2: 69-81. https://doi.org/10.1016/j.imed.2021.08.004
    [6] Kandhavelu J, Subramanian K, Naidoo V, et al. (2024) A novel EGFR inhibitor, HNPMI, regulates apoptosis and oncogenesis by modulating BCL-2/BAX and p53 in colon cancer. Br J Pharmacol 181: 107-124. https://doi.org/10.1111/bph.16141
    [7] Sundaram KKM, Bupesh G, Saravanan KM (2022) Instrumentals behind embryo and cancer: A platform for prospective future in cancer research. AIMS Mol Sci 9: 25-45. https://doi.org/10.3934/molsci.2022002
    [8] Feng Y, Spezia M, Huang S, et al. (2018) Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis 5: 77-106. https://doi.org/10.1016/j.gendis.2018.05.001
    [9] Qian S, Wei Z, Yang W, et al. (2022) The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol 12: 985363. https://doi.org/10.3389/fonc.2022.985363
    [10] Debela DT, Muzazu SG, Heraro KD, et al. (2021) New approaches and procedures for cancer treatment: Current perspectives. SAGE Open Med 9: 20503121211034366. https://doi.org/10.1177/20503121211034366
    [11] Carlson RW, Anderson BO, Chopra R, et al. (2003) Treatment of breast cancer in countries with limited resources. Breast J 9: S67-S74. https://doi.org/10.1046/j.1524-4741.9.s2.6.x
    [12] Bamodu OA, Chung CC, Pisanic TR, et al. (2024) The intricate interplay between cancer stem cells and cell-of-origin of cancer: Implications for therapeutic strategies. Front Oncol 14: 1404628. https://doi.org/10.3389/fonc.2024.1404628
    [13] Bhat GR, Sethi I, Sadida HQ, et al. (2024) Cancer cell plasticity: From cellular, molecular, and genetic mechanisms to tumor heterogeneity and drug resistance. Cancer Metastasis Rev 43: 197-228. https://doi.org/10.1007/s10555-024-10172-z
    [14] Galluzzi L, Vitale I, Aaronson SA, et al. (2018) Molecular mechanisms of cell death: Recommendations of the Nomenclature Committee on Cell Death 2018. Cell Death Differ 25: 486-541. https://doi.org/10.1038/s41418-017-0012-4
    [15] Warren CFA, Wong-Brown MW, Bowden NA (2019) BCL-2 family isoforms in apoptosis and cancer. Cell Death Dis 10: 177. https://doi.org/10.1038/s41419-019-1407-6
    [16] Rabkin CS, Hirt C, Janz S, et al. (2008) t(14;18) Translocations and risk of follicular lymphoma. JNCI Monogr 2008: 48-51. https://doi.org/10.1093/jncimonographs/lgn002
    [17] Roulland S, Lebailly P, Lecluse Y, et al. (2004) Characterization of the t(14;18) BCL2-IGH translocation in farmers occupationally exposed to pesticides. Cancer Res 64: 2264-2269. https://doi.org/10.1158/0008-5472.can-03-3604
    [18] Singh R, Letai A, Sarosiek K (2019) Regulation of apoptosis in health and disease: The balancing act of BCL-2 family proteins. Nat Rev Mol Cell Biol 20: 175-193. https://doi.org/10.1038/s41580-018-0089-8
    [19] Banjara S, Suraweera CD, Hinds MG, et al. (2020) The BCL-2 family: Ancient origins, conserved structures, and divergent mechanisms. Biomolecules 10: 128. https://doi.org/10.3390/biom10010128
    [20] Zografos E, Zagouri F, Kalapanida D, et al. (2019) Prognostic role of microRNAs in breast cancer: A systematic review. Oncotarget 10: 7156-7178. https://doi.org/10.18632/oncotarget.27327
    [21] Muñoz JP, Pérez-Moreno P, Pérez Y, et al. (2023) The role of microRNAs in breast cancer and the challenges of their clinical application. Diagnostics 13: 3072. https://doi.org/10.3390/diagnostics13193072
    [22] Sharma PC, Gupta A (2020) MicroRNAs: Potential biomarkers for diagnosis and prognosis of different cancers. Transl Cancer Res 9: 5798-5818. https://doi.org/10.21037/tcr-20-1294
    [23] Ying SY, Chang DC, Lin SL (2008) The microRNA (miRNA): Overview of the RNA genes that modulate gene function. Mol Biotechnol 38: 257-268. https://doi.org/10.1007/s12033-007-9013-8
    [24] Pekarek L, Torres-Carranza D, Fraile-Martinez O, et al. (2023) An overview of the role of microRNAs on carcinogenesis: A focus on cell cycle, angiogenesis and metastasis. Int J Mol Sci 24: 7268. https://doi.org/10.3390/ijms24087268
    [25] Sharifi Z, Talkhabi M, Taleahmad S (2022) Identification of potential microRNA diagnostic panels and uncovering regulatory mechanisms in breast cancer pathogenesis. Sci Rep 12: 20135. https://doi.org/10.1038/s41598-022-24347-7
    [26] Abdul Manap AS, Wisham AA, Wong FW, et al. (2024) Mapping the function of microRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies. Front Cell Dev Biol 12: 1390704. https://doi.org/10.3389/fcell.2024.1390704
    [27] Kaloni D, Diepstraten ST, Strasser A, et al. (2023) BCL-2 protein family: Attractive targets for cancer therapy. Apoptosis 28: 20-38. https://doi.org/10.1007/s10495-022-01780-7
    [28] O'Day E, Lal A (2010) MicroRNAs and their target gene networks in breast cancer. Breast Cancer Res 12: 201. https://doi.org/10.1186/bcr2484
    [29] Saddam M, Paul SK, Habib MA, et al. (2024) Emerging biomarkers and potential therapeutics of the BCL-2 protein family: The apoptotic and antiapoptotic context. Egypt J Med Hum Genet 25: 12. https://doi.org/10.1186/s43042-024-00485-7
    [30] Wang H, Guo M, Wei H, et al. (2023) Targeting p53 pathways: Mechanisms, structures, and advances in therapy. Sig Transduct Target Ther 8: 92. https://doi.org/10.1038/s41392-023-01347-1
    [31] Elmore S (2007) Apoptosis: A review of programmed cell death. Toxicol Pathol 35: 495-516. https://doi.org/10.1080/01926230701320337
    [32] Jan R, Chaudhry G (2019) Understanding apoptosis and apoptotic pathways targeted cancer therapeutics. Adv Pharm Bull 9: 205-218. https://doi.org/10.15171/apb.2019.024
    [33] Kale J, Osterlund EJ, Andrews DW (2018) BCL-2 family proteins: Changing partners in the dance towards death. Cell Death Differ 25: 65-80. https://doi.org/10.1038/cdd.2017.186
    [34] Letai A, Bassik MC, Walensky LD, et al. (2002) Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell 2: 183-192. https://doi.org/10.1016/S1535-6108(02)00127-7
    [35] Lomonosova E, Chinnadurai G (2008) BH3-only proteins in apoptosis and beyond: An overview. Oncogene 27: S2-S19. https://doi.org/10.1038/onc.2009.39
    [36] Lalier L, Vallette F, Manon S (2022) BCL-2 family members and the mitochondrial import machineries: The roads to death. Biomolecules 12: 162. https://doi.org/10.3390/biom12020162
    [37] Chen D, Frezza M, Schmitt S, et al. (2011) Bortezomib as the first proteasome inhibitor anticancer drug: Current status and future perspectives. Curr Cancer Drug Targets 11: 239-253. https://doi.org/10.2174/156800911794519752
    [38] Harris MH, Thompson CB (2000) The role of the BCL-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ 7: 1182-1191. https://doi.org/10.1038/sj.cdd.4400781
    [39] Jang DM, Oh EK, Hahn H, et al. (2022) Structural insights into apoptotic regulation of human Bfk as a novel BCL-2 family member. Comput Struct Biotechnol J 20: 745-756. https://doi.org/10.1016/j.csbj.2022.01.023
    [40] Kelekar A, Thompson CB (1998) BCL-2-family proteins: The role of the BH3 domain in apoptosis. Trends Cell Biol 8: 324-330. https://doi.org/10.1016/s0962-8924(98)01321-x
    [41] Dadsena S, Jenner A, García-Sáez AJ (2021) Mitochondrial outer membrane permeabilization at the single molecule level. Cell Mol Life Sci 78: 3777-3790. https://doi.org/10.1007/s00018-021-03771-4
    [42] Bender T, Martinou JC (2013) Where killers meet—permeabilization of the outer mitochondrial membrane during apoptosis. Cold Spring Harb Perspect Biol 5: a011106. https://doi.org/10.1101/cshperspect.a011106
    [43] Czabotar PE, Garcia-Saez AJ (2023) Mechanisms of BCL-2 family proteins in mitochondrial apoptosis. Nat Rev Mol Cell Biol 24: 732-748. https://doi.org/10.1038/s41580-023-00629-4
    [44] Peña-Blanco A, García-Sáez AJ (2018) Bax, Bak and beyond—mitochondrial performance in apoptosis. FEBS J 285: 416-431. https://doi.org/10.1111/febs.14186
    [45] MacFarlane LA, Murphy PR (2010) MicroRNA: Biogenesis, function and role in cancer. Curr Genomics 11: 537-561. https://doi.org/10.2174/138920210793175895
    [46] Starega-Roslan J, Koscianska E, Kozlowski P, et al. (2011) The role of the precursor structure in the biogenesis of microRNA. Cell Mol Life Sci 68: 2859-2871. https://doi.org/10.1007/s00018-011-0726-2
    [47] O'Brien J, Hayder H, Zayed Y, et al. (2018) Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol 9: 402. https://doi.org/10.3389/fendo.2018.00402
    [48] Haas G, Cetin S, Messmer M, et al. (2016) Identification of factors involved in target RNA-directed microRNA degradation. Nucleic Acids Res 44: 2873-2887. https://doi.org/10.1093/nar/gkw040
    [49] Bujak M, Ratkaj I, Baus M, et al. (2011) Small interfering RNAs: Heralding a new era in gene therapy. Gene therapy—developments and future perspectives.IntechOpen. https://doi.org/10.5772/20646
    [50] Gu S, Jin L, Zhang F, et al. (2009) Biological basis for restriction of microRNA targets to the 3′ untranslated region in mammalian mRNAs. Nat Struct Mol Biol 16: 144-150. https://doi.org/10.1038/nsmb.1552
    [51] Menon A, Abd-Aziz N, Khalid K, et al. (2022) miRNA: A promising therapeutic target in cancer. Int J Mol Sci 23: 11502. https://doi.org/10.3390/ijms231911502
    [52] Peng Y, Croce CM (2016) The role of microRNAs in human cancer. Signal Transduct Target Ther 1: 15004. https://doi.org/10.1038/sigtrans.2015.4
    [53] Otmani K, Lewalle P (2021) Tumor suppressor miRNA in cancer cells and the tumor microenvironment: Mechanism of deregulation and clinical implications. Front Oncol 11: 708765. https://doi.org/10.3389/fonc.2021.708765
    [54] Spadaccino F, Gigante M, Netti GS, et al. (2021) The ambivalent role of miRNAs in carcinogenesis: Involvement in renal cell carcinoma and their clinical applications. Pharmaceuticals 14: 322. https://doi.org/10.3390/ph14040322
    [55] Shah MY, Ferrajoli A, Sood AK, et al. (2016) microRNA therapeutics in cancer—An emerging concept. EBioMedicine 12: 34-42. https://doi.org/10.1016/j.ebiom.2016.09.017
    [56] Bayir H, Kagan VE (2008) Bench-to-bedside review: Mitochondrial injury, oxidative stress and apoptosis—there is nothing more practical than a good theory. Crit Care 12: 206. https://doi.org/10.1186/cc6779
    [57] Garrido C, Galluzzi L, Brunet M, et al. (2006) Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13: 1423-1433. https://doi.org/10.1038/sj.cdd.4401950
    [58] Adams JM, Cory S (2018) The BCL-2 arbiters of apoptosis and their growing role as cancer targets. Cell Death Differ 25: 27-36. https://doi.org/10.1038/cdd.2017.161
    [59] Garrido-Cano I, Pattanayak B, Adam-Artigues A, et al. (2022) MicroRNAs as a clue to overcome breast cancer treatment resistance. Cancer Metastasis Rev 41: 77-105. https://doi.org/10.1007/s10555-021-09992-0
    [60] Chakrabortty A, Patton DJ, Smith BF, et al. (2023) miRNAs: Potential as biomarkers and therapeutic targets for cancer. Genes 14: 1375. https://doi.org/10.3390/genes14071375
    [61] Hong T, Ding J, Li W (2019) mir-7 reverses breast cancer resistance to chemotherapy by targeting MRP1 and BCL2. Onco Targets Ther 12: 11097-11105. https://doi.org/10.2147/OTT.S213780
    [62] Cittelly DM, Das PM, Salvo VA, et al. (2010) Oncogenic HER2Δ16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis 31: 2049-2057. https://doi.org/10.1093/carcin/bgq192
    [63] Tao L, Wu YQ, Zhang SP (2019) MiR-21-5p enhances the progression and paclitaxel resistance in drug-resistant breast cancer cell lines by targeting PDCD4. Neoplasma 66: 746-755. https://doi.org/10.4149/neo_2018_181207N930
    [64] Manvati S, Mangalhara KC, Kalaiarasan P, et al. (2015) miR-24-2 regulates genes in survival pathway and demonstrates potential in reducing cellular viability in combination with docetaxel. Gene 567: 217-224. https://doi.org/10.1016/j.gene.2015.05.003
    [65] Han X, Li Q, Liu C, et al. (2019) Overexpression miR-24-3p repressed Bim expression to confer tamoxifen resistance in breast cancer. J Cell Biochem 120: 12966-12976. https://doi.org/10.1002/jcb.28568
    [66] Körner C, Keklikoglou I, Bender C, et al. (2013) MicroRNA-31 sensitizes human breast cells to apoptosis by direct targeting of protein Kinase C ϵ (PKCϵ). J Biol Chem 288: 8750-8761.
    [67] Kastl L, Brown I, Schofield AC (2012) miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat 131: 445-454. https://doi.org/10.1007/s10549-011-1424-3
    [68] Bao C, Chen J, Chen D, et al. (2020) MiR-93 suppresses tumorigenesis and enhances chemosensitivity of breast cancer via dual targeting E2F1 and CCND1. Cell Death Dis 11: 618. https://doi.org/10.1038/s41419-020-02855-6
    [69] You F, Luan H, Sun D, et al. (2018) miRNA-106a promotes breast cancer cell proliferation, clonogenicity, migration, and invasion through inhibiting apoptosis and chemosensitivity. DNA Cell Biol 38: 198-207. https://doi.org/10.1089/dna.2018.4282
    [70] Zhang W, Jiang H, Chen Y, et al. (2019) Resveratrol chemosensitizes adriamycin-resistant breast cancer cells by modulating miR-122-5p. J Cell Biochem 120: 16283-16292. https://doi.org/10.1002/jcb.28910
    [71] Xie X, Hu Y, Xu L, et al. (2015) The role of miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance and therapy in human breast cancer. Tumor Biol 36: 7185-7194. https://doi.org/10.1007/s13277-015-3438-7
    [72] Zhou M, Liu Z, Zhao Y, et al. (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic BCL-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285: 21496-21507. https://doi.org/10.1074/jbc.M109.083337
    [73] O'Brien K, Lowry MC, Corcoran C, et al. (2015) miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 6: 32774-32789. https://doi.org/10.18632/oncotarget.5192
    [74] Xiang F, Fan Y, Ni Z, et al. (2019) Ursolic acid reverses the chemoresistance of breast cancer cells to paclitaxel by targeting miRNA-149-5p/MyD88. Front Oncol 9: 00501. https://doi.org/10.3389/fonc.2019.00501
    [75] Zheng Y, Lv X, Wang X, et al. (2016) miR-181b promotes chemoresistance in breast cancer by regulating Bim expression. Oncol Rep 35: 683-690. https://doi.org/10.3892/or.2015.4417
    [76] Zhang Y, He Y, Lu LL, et al. (2019) miRNA-192-5p impacts the sensitivity of breast cancer cells to doxorubicin via targeting peptidylprolyl isomerase A. Kaohsiung J Med Sci 35: 17-23. https://doi.org/10.1002/kjm2.12004
    [77] Yang G, Wu D, Zhu J, et al. (2013) Upregulation of miR-195 increases the sensitivity of breast cancer cells to Adriamycin treatment through inhibition of Raf-1. Oncol Rep 30: 877-889. https://doi.org/10.3892/or.2013.2532
    [78] Aakko S, Straume AH, Birkeland EE, et al. (2019) MYC-induced miR-203b-3p and miR-203a-3p control BCL-xL expression and paclitaxel sensitivity in tumor cells. Transl Oncol 12: 170-179. https://doi.org/10.1016/j.tranon.2018.10.001
    [79] Ye Z, Hao R, Cai Y, et al. (2016) Knockdown of miR-221 promotes the cisplatin-inducing apoptosis by targeting the BIM-Bax/Bak axis in breast cancer. Tumor Biol 37: 4509-4515. https://doi.org/10.1007/s13277-015-4267-4
    [80] Dai H, Xu L, Qian Q, et al. (2019) MicroRNA-222 promotes drug resistance to doxorubicin in breast cancer via regulation of miR-222/bim pathway. Biosci Rep 39: BSR20190650. https://doi.org/10.1042/BSR20190650
    [81] Gu X, Li JY, Guo J, et al. (2015) Influence of MiR-451 on drug resistances of paclitaxel-resistant breast cancer cell line. Med Sci Monit 21: 3291-3297. https://doi.org/10.12659/msm.894475
    [82] Chen X, Wang YW, Xing AY, et al. (2016) Suppression of SPIN1-mediated PI3K–Akt pathway by miR-489 increases chemosensitivity in breast cancer. J Pathol 239: 459-472. https://doi.org/10.1002/path.4743
    [83] Jiang H, Cheng L, Hu P, et al. (2018) MicroRNA‑663b mediates TAM resistance in breast cancer by modulating TP73 expression. Mol Med Rep 18: 1120-1126. https://doi.org/10.3892/mmr.2018.9064
    [84] Ito Y, Inoue A, Seers T, et al. (2017) Identification of targets of tumor suppressor microRNA-34a using a reporter library system. Proc Natl Acad Sci 114: 3927-3932. https://doi.org/10.1073/pnas.1620019114
    [85] Cimmino A, Calin GA, Fabbri M, et al. (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A 102: 13944-13949. https://doi.org/10.1073/pnas.0506654102
    [86] Sims EK, Lakhter AJ, Anderson-Baucum E, et al. (2017) MicroRNA 21 targets BCL2 mRNA to increase apoptosis in rat and human beta cells. Diabetologia 60: 1057-1065. https://doi.org/10.1007/s00125-017-4237-z
    [87] Garrido-Palacios A, Rojas Carvajal AM, Núñez-Negrillo AM, et al. (2023) MicroRNA dysregulation in early breast cancer diagnosis: A systematic review and meta-analysis. Int J Mol Sci 24: 8270. https://doi.org/10.3390/ijms24098270
    [88] Capaccia C, Diverio S, Zampini D, et al. (2022) The complex interaction between P53 and miRNAs joins new awareness in physiological stress responses. Cells 11: 1631. https://doi.org/10.3390/cells11101631
    [89] Arif KMT, Elliott EK, Haupt LM, et al. (2020) Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers 12: 2922. https://doi.org/10.3390/cancers12102922
    [90] Calin GA, Dumitru CD, Shimizu M, et al. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A 99: 15524-15529. https://doi.org/10.1073/pnas.242606799
    [91] Peters L, Meister G (2007) Argonaute proteins: Mediators of RNA silencing. Mol Cell 26: 611-623. https://doi.org/10.1016/j.molcel.2007.05.001
    [92] Ma B, Wang S, Wu W, et al. (2023) Mechanisms of circRNA/lncRNA-miRNA interactions and applications in disease and drug research. Biomed Pharmacother 162: 114672. https://doi.org/10.1016/j.biopha.2023.114672
    [93] Fadeel B, Orrenius S (2005) Apoptosis: A basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258: 479-517. https://doi.org/10.1111/j.1365-2796.2005.01570.x
    [94] Si W, Shen J, Zheng H, et al. (2019) The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenet 11: 25. https://doi.org/10.1186/s13148-018-0587-8
    [95] Mohammad RM, Muqbil I, Lowe L, et al. (2015) Broad targeting of resistance to apoptosis in cancer. Semin Cancer Biol 35: S78-S103. https://doi.org/10.1016/j.semcancer.2015.03.001
    [96] Callens M, Kraskovskaya N, Derevtsova K, et al. (2021) The role of BCL-2 proteins in modulating neuronal Ca2+ signaling in health and in Alzheimer's disease. BBA-Mol Cell Res 1868: 118997. https://doi.org/10.1016/j.bbamcr.2021.118997
    [97] D'Aguanno S, Brignone M, Scalera S, et al. (2024) BCL-2 dependent modulation of Hippo pathway in cancer cells. Cell Commun Signal 22: 277. https://doi.org/10.1186/s12964-024-01647-1
    [98] Abaza A, Vasavada AM, Sadhu A, et al. (2022) A systematic review of apoptosis in correlation with cancer: Should apoptosis be the ultimate target for cancer treatment?. Cureus 14: e28496. https://doi.org/10.7759/cureus.28496
    [99] Huska J, Lamb HM, Hardwick JM (2019) Overview of BCL-2 family proteins and therapeutic potentials. BCL-2 family proteins. Methods in molecular biology. New York: Humana Press 1-21. https://doi.org/10.1007/978-1-4939-8861-7_1
    [100] Yap JL, Chen L, Lanning ME, et al. (2017) Expanding the cancer arsenal with targeted therapies: Disarmament of the antiapoptotic BCL-2 proteins by small molecules. J Med Chem 60: 821-838. https://doi.org/10.1021/acs.jmedchem.5b01888
    [101] Tassone P, Di Martino MT, Arbitrio M, et al. (2023) Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study. J Hematol Oncol 16: 68. https://doi.org/10.1186/s13045-023-01468-8
    [102] Qassem S, Breier D, Naidu GS, et al. (2024) Unlocking the therapeutic potential of locked nucleic acids through lipid nanoparticle delivery. Mol Ther Nucl Acids 35: 102224. https://doi.org/10.1016/j.omtn.2024.102224
    [103] Riolo G, Cantara S, Marzocchi C, et al. (2020) miRNA targets: From prediction tools to experimental validation. Methods Protoc 4: 1. https://doi.org/10.3390/mps4010001
    [104] Hersh AM, Alomari S, Tyler BM (2022) Crossing the blood-brain barrier: Advances in nanoparticle technology for drug delivery in neuro-oncology. Int J Mol Sci 23: 4153. https://doi.org/10.3390/ijms23084153
  • This article has been cited by:

    1. Dongfei Gao, A deep learning approach for energy management systems in smart buildings towards a low-carbon economy, 2025, 20, 1748-1325, 1136, 10.1093/ijlct/ctaf063
  • Reader Comments
  • © 2025 the Author(s), licensee AIMS Press. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

Metrics

Article views(368) PDF downloads(51) Cited by(0)

/

DownLoad:  Full-Size Img  PowerPoint
Return
Return

Catalog